files/journal/2022-09-03_18-51-40-000000_599.png

Research Journal of Medical Sciences

ISSN: Online 1993-6095
ISSN: Print 1815-9346
186
Views
21
Downloads

Weekly Versus three Weekly Concurrent Chemoradiotherapy in Upstaged Head and Neck Cancers‐A Comparative Study

Garima Uikey, Vikas Pal, Hemant Kumar Ahirwar and Abhishek Pratap Singh
Page: 335-341 | Received 30 Mar 2024, Published online: 09 May 2024

Full Text Reference XML File PDF File

Abstract

The head and neck cancers rank among the top 10 cancers globally. A huge population with newly diagnosed cancers is registered in India every year. Of these oral cancers are the most common in India. Surgery forms the mainstay of treatment. Concurrent chemoradiotherapy has shown better results in comparison to surgery alone in advanced cases. Cisplatin is the best radio sensitizer and has been accepted as the standard reference regimen. The present study was carried out to compare two different dosing schedules of cisplatin in terms of tolerance and response to the treatment. The present prospective, comparative study was carried out in the Department of Radiation Oncology, Government Cancer Hospital, Indore. 60 patients with local advanced head and neck cancers were included, divided into two arms. Arm‐A with 30 patients received radical radiotherapy with cisplatin given every week during the radiotherapy sessions, while Arm‐B patients received radical radiotherapy with concurrent cisplatin on day 1, 22 and 43. The RECIST 1.1 criteria was used for finding out the response. Proportional comparison was done using Pearson Chi‐square test. There was a male preponderance in both the arms. 41.7% had moderately and 31.7% had poorly differentiated histological carcinoma grades. 55% had proliferative growth. 66.7% were in stage III and 33.3% were in stage IV disease. 60% in Arm‐A and 70% in Arm‐B had complete response. 10% in Arm‐A and 3% in Arm‐B had progression of the disease. Mucositis, dermatitis, xerostomia, trismus, dysphagia, anemia, thrombocytopenia, etc. all were comparable between the two arms (p>0.05). Our study found that cisplatin if given on day 1, 22 and 43 concurrently with radiation therapy has better outcome with lower incidence of disease progression.


How to cite this article:

Garima Uikey, Vikas Pal, Hemant Kumar Ahirwar and Abhishek Pratap Singh. Weekly Versus three Weekly Concurrent Chemoradiotherapy in Upstaged Head and Neck Cancers‐A Comparative Study.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.6.335.341
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.6.335.341